Abstract
BackgroundPrevious ischemic stroke is a predictor of recurrent ischemic stroke after an acute myocardial infarction (AMI). Dual antiplatelet therapy, including a P2Y12-inhibitor, is important in secondary prevention after AMI. Ticagrelor, a P2Y12-inhibitor, is more potent than the commonly used clopidogrel. Here, we evaluated the impact of ticagrelor on the risk of ischemic stroke following AMI in patients with previous ischemic stroke.MethodsData for patients with AMI that had a previous ischemic stroke were obtained from the Swedish Registry of Information and Knowledge about Swedish Heart Intensive Care Admissions. Patients were assigned to early and late cohorts, each covering a two-year time period before and after, respectively, the introduction of ticagrelor prescriptions (20 Dec 2011). Patients in the early cohort (n = 1633) were treated with clopidogrel (100%); those in the late cohort (n = 1642) were treated with either clopidogrel (66.3%) or ticagrelor (33.7%). We assessed the risk of ischemic stroke and intracranial bleeding over time with Kaplan-Meier analyses. We identified predictors of ischemic stroke with multivariable Cox regression analyses.ResultsOf 3275 patients, 311 experienced ischemic stroke after AMI. Cumulative Kaplan-Meier incidence estimates of ischemic stroke within one year after AMI were 12.1% versus 8.6% for the early and late cohorts, respectively (p<0.01). Intracranial bleeding incidences (1.2% versus 1.5%) were similar between the two cohorts.ConclusionsTicagrelor introduction was associated with a lower rate of ischemic stroke, with no increase in intracranial bleeding, in an AMI population with a history of ischemic stroke.
Highlights
Cardiovascular disease is a leading cause of death and disability
Cumulative Kaplan-Meier incidence estimates of ischemic stroke within one year after acute myocardial infarction (AMI) were 12.1% versus 8.6% for the early and late cohorts, respectively (p
Ticagrelor introduction was associated with a lower rate of ischemic stroke, with no increase in intracranial bleeding, in an AMI population with a history of ischemic stroke
Summary
Cardiovascular disease is a leading cause of death and disability. It affects millions of people annually. In the international REduction of Atherothrombosis for Continued Health (REACH) registry, 11.25% of patients with coronary artery disease had a history of ischemic stroke, which is often associated with significant co-morbidities[7]. These patients are routinely encountered in clinical practice and constitute an important high-risk population with a worse prognosis than the general AMIpopulation. Previous ischemic stroke is a predictor of recurrent ischemic stroke after an acute myocardial infarction (AMI). We evaluated the impact of ticagrelor on the risk of ischemic stroke following AMI in patients with previous ischemic stroke
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
